Similar articles

Abstract: Liver is one of the most important organs in energy metabolism. Most plasma apolipoproteins and endogenous lipids and lipoproteins are synthesized in the liver. It depends on the integrity of liver cellular function, which ensures homeostasis of lipid and lipoprotein metabolism. When liver cancer occurs, these processes are impaired and the plasma lipid and lipoprotein patterns may be changed. liver cancer is the fifth common malignant tumor worldwide, and is closely related to the infections of hepatitis B virus (HBV) and hepatitis C virus (HCV). HBV and HCV infections are quite common in China and other Southeast Asian countries. In addition, liver cancer is often followed by a procession of chronic hepatitis or cirrhosis, so that hepatic function is damaged obviously on these bases, which may significantly influence lipid and lipoprotein metabolism in vivo. In this review we summarize the clinical significance of lipid and lipoprotein metabolism under liver cancer.

[1] Albers, J.J., Adolphson, J.L., Hazzard, W.R., 1977. Radioimmunoassay of human plasma Lp(a) lipoprotein. J. Lipid. Res., 18:331-338.

[2] Artl, A., Marsche, G., Pussinen, P., Knipping, G., Sattler, W., Malle, E., 2002. Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int. J. Biochem. Cell Biol., 34(4):370-381.

[3] Assmann, G., Schriewer, H., 1980. HDL cholesterol: biochemical aspects. Klin. Wochenschr., 58(15):749-756 (in German).

[4] Bae, E.S., Jung, J.W., Jang, J.Y., Choi, S.K., Yoon, S.H.C., 2002. Clinical significance of correlation between COX-2 and CD34-expression in dysplastic nodules. Hepatology, 36:445A.

[5] Bamberger, M., Glick, J.M., Rothblat, G.H., 1983. Hepatic lipase stimulates the uptake of high density lipoprotein cholesterol by hepatoma cells. J. Lipid. Res., 24:869-876.

[6] Basili, S., Andreozzi, P., Vieri, M., Maurelli, M., Cara, D., Cordova, C., Alessandri, C., 1997. Lipoprotein(a) serum levels in patients with hepatocarcinoma. Clin. Chim. Acta, 262(1-2):53-60.

[7] Bégin, M.E., Das, U.N., Ells, G., Horrobin, D.F., 1985. Selective killing of human cancer cells by polyunsaturated fatty acids. Prostaglandins Leukot. Med., 19(2):177-186.

[8] Bégin, M.E., Ells, G., Das, U.N., Horrobin, D.F., 1986. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J. Natl. Cancer Inst., 77:1053-1062.

[9] Booth, S., Clifton, P.M., Nestel, P.J., 1991. Lack of effect of acute alcohol ingestion on plasma lipids. Clin. Chem., 37:1649.

[10] Bravo, E., Carpinelli, G., Proietti, E., Belardelli, F., Cantafora, A., Podo, F., 1990. Alterations of lipid composition in Friend leukemia cell tumors in mice treated with tumor necrosis factor-alpha. FEBS Lett., 260(2):225-228.

[11] Brinton, E.A., 1996. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler. Thromb. Vasc. Biol., 16:431-440.

[12] Busch, S.J., Barnhart, R.L., Martin, G.A., Fitzgerald, M.C., Yates, M.T., Mao, S.J., Thomas, C.E., Jackson, R.L., 1994. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J. Biol. Chem., 269:16376-16382.

[13] Cambien, F., Ducimetiere, P., Richard, J., 1980. Total serum cholesterol and cancer mortality in a middle-aged male population. Am. J. Epidemiol., 112:388-394.

[14] Carter, C.A., 2000. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr. Drug Targets, 1(2):163-183.

[15] Casey, P.J., Solski, P.A., Der, C.J., Buss, J.E., 1989. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. (USA), 86(21):8323-8327.

[16] Charpentier, D., Tremblay, C., Rassart, E., Rhainds, D., Auger, A., Milne, R.W., Brissette, L., 2000. Low- and high-density lipoprotein metabolism in HepG2 cells expressing various levels of apolipoprotein E. Biochemistry, 39(51):16084-16091.

[17] Chu, A.C., Tsang, S.Y., Lo, E.H., Fung, K.P., 2001. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci., 70(5):591-601.

[18] Cicognani, C., Malavolti, M., Morselli-Labate, A.M., Zamboni, L., Sama, C., Barbara, L., 1997. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch. Intern. Med., 157(7):792-796.

[19] Cooper, M.E., Akdeniz, A., Hardy, K.J., 1996. Effects of liver transplantation and resection on lipid parameters: a longitudinal study. Aust. N. Z. J. Surg., 66:743-746.

[20] Cowen, A.E., Campbell, C.B., 1977. Bile salt metabolism. I. The physiology of bile salts. Aust. N. Z. J. Med., 7:579-586.

[21] Curtiss, L.K., Boisvert, W.A., 2000. Apolipoprotein E and atherosclerosis. Curr. Opin. Lipidol., 11(3):243-251.

[22] Davis, R., Bryson, H.M., 1994. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs, 47:677-700.

[23] de Alaniz, M.J., Marra, C.A., 1994. Role of delta 9 desaturase activity in the maintenance of high levels of monoenoic fatty acids in hepatoma cultured cells. Mol. Cell. Biochem., 137(1):85-90.

[24] Dessì, S., Batetta, B., Pulisci, D., Spano, O., Anchisi, C., Tessitore, L., Costelli, P., Baccino, F.M., Aroasio, E., Pani, P., 1994. Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer, 73(2):253-258.

[25] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest., 115(5):1343-1351.

[26] Dugi, K.A., Vaisman, B.L., Sakai, N., Knapper, C.L., Meyn, S.M., Brewer, H.B.Jr, Santamarina-Fojo, S., 1997. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. J. Lipid. Res., 38:1822-1832.

[27] Dugi, K.A., Brandauer, K., Schmidt, N., Nau, B., Schneider, J.G., Mentz, S., Keiper, T., Schaefer, J.R., Meissner, C., Kather, H., Bahner, M.L., Fiehn, W., Kreuzer, J., 2001. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation, 104:3057-3062.

[28] Eggerman, T.L., Hoeg, J.M., Meng, M.S., Tombragel, A., Bojanovski, D., Brewer, H.B.Jr, 1991. Differential tissue-specific expression of human apoA-I and apoA-II. J. Lipid. Res., 32:821-828.

[29] Eisenberg, S., Levy, R.I., 1975. Lipoprotein metabolism. Adv. Lipid. Res., 13:1-89.

[30] Fazio, S., Yao, Z., 1995. The enhanced association of apolipoprotein E with apolipoprotein B-containing lipoproteins in serum-stimulated hepatocytes occurs intracellularly. Arterioscler. Thromb. Vasc. Biol., 15:593-600.

[31] Fielding, C.J., Fielding, P.E., 1995. Molecular physiology of reverse cholesterol transport. J. Lipid. Res., 36:211-228.

[32] Fox, J.C., Hay, R.V., 1992. Eicosapentaenoic acid inhibits cell growth and triacylglycerol secretion in McA-RH7777 rat hepatoma cultures. Biochem. J., 286(Pt 1):305-312.

[33] Frederick, G.L., Begg, R.W., 1956. A study of hyperlipemia in the tumor-bearing rat. Cancer Res., 16:548-552.

[34] Fujiyama-Fujiwara, Y., Umeda, R., Igarashi, O., 1992. Metabolism of arachidonic, eicosapentaenoic, and docosahexaenoic acids in HepG2 cells and rat hepatocytes. J. Nutr. Sci. Vitaminol. (Tokyo), 38:329-334.

[35] Funahashi, T., Yokoyama, S., Yamamoto, A., 1989. Association of apolipoprotein E with the low density lipoprotein receptor: demonstration of its cooperativity on lipid microemulsion particles. J. Biochem. (Tokyo), 105:582-587.

[36] Garcia, A., Barbaras, R., Collet, X., Bogyo, A., Chap, H., Perret, B., 1996. High-density lipoprotein 3 receptor-dependent endocytosis pathway in a human hepatoma cell line (HepG2). Biochemistry, 35(40):13064-13071.

[37] Geiss, H.C., Ritter, M.M., Richter, W.O., Schwandt, P., Zachoval, R., 1996. Low lipoprotein (a) levels during acute viral hepatitis. Hepatology, 24(6):1334-1337.

[38] Genest, J.J., Mcnamara, J.R., Ordovas, J.M., Martin-Munley, S., Jenner, J.L., Millar, J., Salem, D.N., Schaefer, E.J., 1990. Effect of elective hospitalization on plasma lipoprotein cholesterol and apolipoproteins A-I, B and Lp(a). Am. J. Cardiol., 65(9):677-679.

[39] Gifford, G.E., Lohmann-Matthes, M.L., 1987. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J. Natl. Cancer Inst., 78:121-124.

[40] Greco, A.V., Mingrone, G., Gasbarrini, G., 1995. Free fatty acid analysis in ascitic fluid improves diagnosis in malignant abdominal tumors. Clin. Chim. Acta, 239(1):13-22.

[41] Grünler, J., Olsson, J.M., Dallner, G., 1995. Estimation of dolichol and cholesterol synthesis in microsomes and peroxisomes isolated from rat liver. FEBS Lett., 358(3):230-232.

[42] Guan, Z.Q., Dong, Z.H., Wang, Q.H., Cao, D.X., Fang, Y.Y., Li, H.T., Uchenna, H.I., 2004. Cost of chronic hepatitis B infection in China. J. Clin. Gastroenterol., 38(Suppl. 3):175-178.

[43] Hachem, H., Favre, G., Raynal, G., Blavy, G., Canal, P., Soula, G., 1986. Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis. J. Clin. Chem. Clin. Biochem., 24:161-166.

[44] Hanai, T., Hashimoto, T., Nishiwaki, K., Ono, M., Akamo, Y., Tanaka, M., Mizuno, I., Yura, J., 1993. Comparison of prostanoids and their precursor fatty acids in human hepatocellular carcinoma and noncancerous reference tissues. J. Surg. Res., 54(1):57-60.

[45] Heeren, J., Grewal, T., Laatsch, A., Becker, N., Rinninger, F., Rye, K.A., Beisiegel, U., 2004. Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J. Biol. Chem., 279(53):55483-55492.

[46] Higuchi, K., Hospattankar, A.V., Law, S.W., Meglin, N., Cortright, J., Brewer, H.B.Jr, 1988. Human apolipoprotein B (apoB) mRNA: identification of two distinct apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA containing a premature in-frame translational stop codon, in both liver and intestine. Proc. Natl. Acad. Sci. (USA), 85(6):1772-1776.

[47] Hildebrandt, L.A., Spennetta, T., Elson, C., Shrago, E., 1995. Utilization and preferred metabolic pathway of ketone bodies for lipid synthesis by isolated rat hepatoma cells. Am. J. Physiol., 269:C22-C27.

[48] Hirano, R., Igarashi, O., Kondo, K., Itakura, H., Matsumoto, A., 2001. Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells. Lipids, 36(4):401-406.

[49] Hiraoka, H., Yamashita, S., Matsuzawa, Y., Kubo, M., Nozaki, S., Sakai, N., Hirano, K., Kawata, S., Tarui, S., 1993. Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology, 18(1):103-110.

[50] Hoeg, J.M., Demosky, S.J.Jr, Edge, S.B., Gregg, R.E., Osborne, J.C.Jr, Brewer, H.B.Jr, 1985. Characterization of a human hepatic receptor for high density lipoproteins. Arteriosclerosis, 5:228-237.

[51] Hostmark, A.T., Lystad, E., 1992. Growth inhibition of human hepatoma cells (HepG2) by polyunsaturated fatty acids. Protection by albumin and vitamin E. Acta Physiol. Scand., 144:83-88.

[52] Hu, K.Q., 2003. Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases. Prostaglandins Leukot. Essent. Fatty Acids, 69(5):329-337.

[53] Huard, K., Bourgeois, P., Rhainds, D., Falstrault, L., Cohn, J.S., Brissette, L., 2005. Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells. Int. J. Biochem. Cell Biol., 37(6):1308-1318.

[54] Iguchi, T., Takasugi, N., Nishimura, N., Kusunoki, S., 1989. Correlation between mammary tumor and blood glucose, serum insulin, and free fatty acids in mice. Cancer Res., 49:821-825.

[55] Kader, A., Davis, P.J., Kara, M., Liu, H., 1998. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J. Control. Rel., 55(2-3):231-243.

[56] Kanel, G.C., Radvan, G., Peters, R.L., 1983. High-density lipoprotein cholesterol and liver disease. Hepatology, 3:343-348.

[57] Kang, S.K., Chung, T.W., Lee, J.Y., Lee, Y.C., Morton, R.E., Kim, C.H., 2004. The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J. Biol. Chem., 279(27):28106-28112.

[58] Katsuramaki, T., Hirata, K., Kimura, Y., Nagayama, M., Meguro, M., Kimura, H., Honma, T., Furuhata, T., Hideki, U., Hata, F., Mukaiya, M., 2002. Changes in serum levels of apolipoprotein A-1 as an indicator of protein metabolism after hepatectomy. Wound Repair and Regeneration, 10(1):77-82.

[59] Keler, T., Barker, C.S., Sorof, S., 1992. Specific growth stimulation by linoleic acid in hepatoma cell lines transfected with the target protein of a liver carcinogen. Proc. Natl. Acad. Sci. (USA), 89(11):4830-4834.

[60] Koga, H., Sakisaka, S., Ohishi, M., Kawaguchi, T., Taniguchi, E., Sasatomi, K., Harada, M., Kusaba, T., Tanaka, M., Kimura, R., et al., 1999. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 29(3):688-696.

[61] Kondo, M., Yamamoto, H., Nagano, H., Okami, J., Ito, Y., Shimizu, J., Eguchi, H., Miyamoto, A., Dono, K., Umeshita, K., et al., 1999. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res., 5:4005-4012.

[62] Kostner, G.M., 1983. Apolipoproteins and lipoproteins of human plasma: significance in health and in disease. Adv. Lipid. Res., 20:1-43.

[63] Kraft, H.G., Menzel, H.J., Hoppichler, F., Vogel, W., Utermann, G., 1989. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J. Clin. Invest., 83:137-142.

[64] Krempler, F., Kostner, G.M., Bolzano, K., Sandhofer, F., 1980. Turnover of lipoprotein (a) in man. J. Clin. Invest., 65:1483-1490.

[65] Krempler, F., Kostner, G.M., Roscher, A., Haslauer, F., Bolzano, K., Sandhofer, F., 1983. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J. Clin. Invest., 71:1431-1441.

[66] Krieger, M., 1999. Charting the fate of the “good cholesterol”: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu. Rev. Biochem., 68(1):523-558.

[67] Krisans, S.K., 1996. Cell compartmentalization of cholesterol biosynthesis. Ann. N. Y. Acad. Sci., 804(1):142-164.

[68] Kumar, K., Sachdanandam, P., Arivazhagan, R., 1991. Studies on the changes in plasma lipids and lipoproteins in patients with benign and malignant breast cancer. Biochem. Int., 23:581-589.

[69] Langstein, H.N., Norton, J.A., 1991. Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North. Am., 5:103-123.

[70] Law, M.R., Thompson, S.G., 1991. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes and Control, 2(4):253-261.

[71] Levi, S., 1972. Estimation of fetal age: ultrasonics and other methods. J. Gynecol. Obstet. Biol. Reprod. (Paris), 1:314-315.

[72] Lewis, G.F., Rader, D.J., 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 96(12):1221-1232.

[73] Lin, C., Blank, W., Ceriani, R.L., Baker, N., 1992. Effect of human mammary MX-1 tumor on plasma free fatty acids in fasted and fasted-refed nude mice. Lipids, 27(1):33-37.

[74] Lou, B., Liao, X.L., Wu, M.P., Cheng, P.F., Yin, C.Y., Fei, Z., 2005. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J. Gastroenterol., 11:954-959.

[75] Maeda, S., Abe, A., Seishima, M., Makino, K., Noma, A., Kawade, M., 1989. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis, 78(2-3):145-150.

[76] Malaguarnera, M., Trovato, G., Restuccia, S., Giugno, I., Franze, C.M., Receputo, G., Siciliano, R., Motta, M., Trovato, B.A., 1994. Treatment of nonresectable hepatocellular carcinoma: review of the literature and meta-analysis. Adv. Ther., 11:303-319.

[77] Malaguarnera, M., Giugno, I., Trovato, B.A., Panebianco, M.P., Restuccia, N., Ruello, P., 1996. Lipoprotein(a) in cirrhosis. A new index of liver functions? Curr. Med. Res. Opin., 13:479-485.

[78] Malmendier, C.L., Lontie, J.F., Mathe, D., Adam, R., Bismuth, H., 1992. Lipid and apolipoprotein changes after orthotopic liver transplantation for end-stage liver diseases. Clin. Chim. Acta, 209(3):169-177.

[79] Marques-Vidal, P., Azema, C., Collet, X., Vieu, C., Chap, H., Perret, B., 1994. Hepatic lipase promotes the uptake of HDL esterified cholesterol by the perfused rat liver: a study using reconstituted HDL particles of defined phospholipid composition. J. Lipid. Res., 35:373-384.

[80] Matsuura, T., Koga, S., Ibayashi, H., 1988. Increased proportion of proapolipoprotein A-I in HDL from patients with liver cirrhosis and hepatitis. Gastroenterol. Jpn., 23:394-400.

[81] Mendez, A.J., Oram, J.F., Bierman, E.L., 1991. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J. Biol. Chem., 266:10104-10111.

[82] Mermier, P., Baker, N., 1974. Flux of free fatty acids among host tissues, ascites fluid, and Ehrlich ascites carcinoma cells. J. Lipid. Res., 15:339-351.

[83] Miura, Y., Ono, K., Okauchi, R., Yagasaki, K., 2004. Inhibitory effect of coffee on hepatoma proliferation and invasion in culture and on tumor growth, metastasis and abnormal lipoprotein profiles in hepatoma-bearing rats. J. Nutr. Sci. Vitaminol. (Tokyo), 50:38-44.

[84] Montaguti, U., Sangiorgi, Z., Descovich, G.C., 1975. The liver and abnormal lipoproteins. Minerva. Med., 66:3428-3437.

[85] Motta, M., Giugno, I., Ruello, P., Pistone, G., Di Fazio, I., Malaguarnera, M., 2001. Lipoprotein(a) behaviour in patients with hepatocellular carcinoma. Minerva. Med., 92:301-305.

[86] Mulcahy, J.V., Riddell, D.R., Owen, J.S., 2004. Human scavenger receptor class B type II (SR-BII) and cellular cholesterol efflux. Biochem. J., 377:741-747.

[87] Nissen, N.N., Martin, P., 2002. Hepatocellular carcinoma: the high-risk patient. J. Clin. Gastroenterol., 35(5):S79-S85.

[88] Ockner, R.K., Kaikaus, R.M., Bass, N.M., 1993. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology, 18(3):669-676.

[89] Okuno, K., Jinnai, H., Lee, Y.S., Nakamura, K., Hirohata, T., Shigeoka, H., Yasutomi, M., 1995. A high level of prostaglandin E2 (PGE2) in the portal vein suppresses liver-associated immunity and promotes liver metastases. Surg. Today, 25(11):954-958.

[90] Ooi, K., Shiraki, K., Sakurai, Y., Morishita, Y., Nobori, T., 2005. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int. J. Mol. Med., 15:655-660.

[91] Palut, D., 1997. Proliferation of peroxisomes and the hepatocarcinogenic process. Rocz. Panstw. Zakl. Hig., 48:1-11.

[92] Pangburn, S.H., Newton, R.S., Chang, C.M., Weinstein, D.B., Steinberg, D., 1981. Receptor-mediated catabolism of homologous low density lipoproteins in cultured pig hepatocytes. J. Biol. Chem., 256:3340-3347.

[93] Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., 2001. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer, 94(2):153-156.

[94] Perletti, G., Tessitore, L., Sesca, E., Pani, P., Dianzani, M.U., Piccinini, F., 1996. Epsilon PKC acts like a marker of progressive malignancy in rat liver, but fails to enhance tumorigenesis in rat hepatoma cells in culture. Biochem. Biophys. Res. Commun., 221(3):688-691.

[95] Phillips, G.B., 1960. The lipid composition of serum in patients with liver disease. J. Clin. Invest., 39:1639-1650.

[96] Popescu, I., Simionescu, M., Tulbure, D., Sima, A., Catana, C., Niculescu, L., Hancu, N., Gheorghe, L., Mihaila, M., Ciurea, S., Vidu, V., 2003. Homozygous familial hypercholesterolemia: specific indication for domino liver transplantation. Transplantation, 76(9):1345-1350.

[97] Ramesh, G., Das, U.N., 1995. Effect of dietary fat on diethylnitrosamine induced hepatocarcinogenesis in Wistar rats. Cancer Lett., 95(1-2):237-245.

[98] Rinninger, F., Mann, W.A., Kaiser, T., Ahle, S., Meyer, N., Greten, H., 1998. Hepatic lipase mediates an increase in selective uptake of high-density lipoprotein-associated cholesteryl esters by human Hep 3B hepatoma cells in culture. Atherosclerosis, 141(2):273-285.

[99] Rothblat, G.H., Phillips, M.C., 1986. Cholesterol efflux: mechanism and regulation. Adv. Exp. Med. Biol., 201:195-204.

[100] Rubies-Prat, J., Masana, L., Masdeu, S., Nubiola, A.R., Chacon, P., 1983. Hypercholesterolemia associated with hepatocarcinoma. Med. Clin. (Barc), 80:175-176.

[101] Samonakis, D.N., Koutroubakis, I.E., Sfiridaki, A., Malliraki, N., Antoniou, P., Romanos, J., Kouroumalis, E.A., 2004. Hypercoagulable states in patients with hepatocellular carcinoma. Dig. Dis. Sci., 49(5):854-858.

[102] Santamarina-Fojo, S., Haudenschild, C., Amar, M., 1998. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr. Opin. Lipidol., 9:211-219.

[103] Sherlock, D.S., 1995. Alcoholic liver disease. Lancet, 345(8944):227-229.

[104] Sherlock, S., Dooley, I., 1993. Disease of the Liver and Biliary System, 9th Ed. Kubik Fine Books Ltd., USA, p.503-531.

[105] Shi, J., Zhu, L., Liu, S., Xie, W.F., 2005. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br. J. Cancer, 92(5):607-612.

[106] Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., Yashima, K., Kishimoto, Y., Kawasaki, H., 1999. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology, 46:407-412.

[107] Silver, D.L., Wang, N., Tall, A.R., 2000. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. J. Clin. Invest., 105:151-159.

[108] Skipski, V.P., Barclay, M., Archibald, F.M., Stock, C.C., 1975. Tumor proteolipids. Prog. Biochem. Pharmacol., 10:112-134.

[109] Spector, A.A., 1967. The importance of free fatty acid in tumor nutrition. Cancer Res., 27:1580-1586.

[110] Sviridov, D., Fidge, N., 1995. Pathway of cholesterol efflux from human hepatoma cells. Biochim. Biophys. Acta, 1256:210-220.

[111] Sviridov, D., Nestel, P., 2002. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis, 161(2):245-254.

[112] Sviridov, D., Sasahara, T., Pyle, L.E., Nestel, P.J., Fidge, N.H., 1997. Antibodies against high-density lipoprotein binding proteins enhance high-density lipoprotein uptake but do not affect cholesterol efflux from rat hepatoma cells. Int. J. Biochem. Cell Biol., 29(4):583-588.

[113] Tall, A.R., Jiang, X., Luo, Y., Silver, D., 2000. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol., 20:1185-1188.

[114] Tan, K.C., Shiu, S.W., Pang, R.W., Kung, A.W., 1998. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin. Endocrinol. (Oxf), 48(2):187-194.

[115] Tietge, U.J., Boker, K.H., Bahr, M.J., Weinberg, S., Pichlmayr, R., Schmidt, H.H., Manns, M.P., 1998. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology, 45:2255-2260.

[116] Tracey, K.J., Lowry, S.F., Cerami, A., 1988. Cachectin: a hormone that triggers acute shock and chronic cachexia. J. Infect. Dis., 157:413-420.

[117] Trigatti, B., Rigotti, A., Krieger, M., 2000. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr. Opin. Lipidol., 11(2):123-131.

[118] Tu, L.C., Chou, C.K., Chen, H.C., Yeh, S.F., 2001. Protein kinase C-mediated tyrosine phosphorylation of paxillin and focal adhesion kinase requires cytoskeletal integrity and is uncoupled to mitogen-activated protein kinase activation in human hepatoma cells. J. Biomed. Sci., 8(2):184-190.

[119] von Eckardstein, A., Huang, Y., Assmann, G., 1994. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr. Opin. Lipidol., 5(6):404-416.

[120] Williams, R.R., Sorlie, P.D., Feinleib, M., Mcnamra, P.M., Kannel, W.B., Dawber, T.R., 1981. Cancer incidence by levels of cholesterol. JAMA, 245(3):247-252.

[121] Zhang, S.W., Li, L.D., Lu, F.Z., 1999. Mortality of primary liver cancer in China from 1990 through 1992. Chinese Journal of Oncology, 21:245-249 (in Chinese).